Insmed Q3 2024 GAAP EPS $(1.27) Misses $(1.21) Estimate, Sales $93.42M Beat $93.01M Estimate
Portfolio Pulse from Benzinga Newsdesk
Insmed reported Q3 2024 earnings with a GAAP EPS of $(1.27), missing the estimate of $(1.21). However, sales were $93.42M, beating the $93.01M estimate and showing an 18.15% increase from last year.
October 31, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Insmed's Q3 2024 earnings report showed a miss on EPS but a beat on sales, with a significant year-over-year sales increase.
The EPS miss suggests potential concerns about profitability, but the sales beat and significant year-over-year growth indicate strong revenue performance. This mixed result may lead to neutral short-term stock movement as investors weigh profitability against revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100